Navigation Links
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator
Date:11/13/2009

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator. Kim Eldridge, Registered Nurse, with over 10 years of clinical experience in complex wound care, is a pioneer in the field of wound care; and is dedicated to providing the highest standards of care, improving clinical outcomes, emphasizing patient education, and ensuring healthcare accessibility and cost-efficiency.

(PRWEB) November 13, 2009 --

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator.

Kim Eldridge, Registered Nurse, was born and raised in Meridian, Mississippi, and has over 10 years of clinical experience in complex wound care. Her commitment to provide the highest standards of wound care, while improving clinical outcomes and emphasizing patient education, and her passion for ensuring healthcare accessibility and cost-efficiency, make Kim a pioneer in the field of wound care.

Kim has been a surgical nurse for over 17 years. She works exclusively with a general surgeon who specializes in wound care, hyperbaric therapy, and limb salvage. She provides surgical wound care in both acute and long term settings, and also consults for major wound care companies and organizations nationwide. She has published several posters and articles in the field of wound care education. Kim is a Registered Nurse First Assistant, and is a certified surgical, foot care and wound care nurse.

Maggie Jankowski, COO of Wake Pharma US, Inc. commented, “Kim Eldridge has been an invaluable resource to the Wound Be Gone® brand. Her clinical insight and experience has been a tremendous asset to our development team. We believe that Kim Eldridge, RN, will help us accelerate the growth of our product line.”

Kim Eldridge stated, “I am very pleased to accept the position of Coordinator & Clinical Wound Specialist Educator and to have the opportunity to contribute to the company’s clinical mission. My clinical experience with Wound Be Gone® has produced impressive results with improved wound healing trajectories. Wound Be Gone® is placing wound care into the hands of people who might otherwise suffer or whose wound problems might escalate to need for expensive, invasive medical intervention.”

Wound-Be-Gone® is a novel hydrophilic gel that has demonstrated enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action is related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.

About Wake Pharma US, Inc:

Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharma US, Inc specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharma US, Inc please visit our website at www.wakepharmaus.com

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3194034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator 
(Date:9/19/2017)... ... September 19, 2017 , ... First Choice Emergency Room , ... Howard Ng, as the new Medical Director of its Pflugerville- FM 685 facility. ... Director of our Pflugerville- FM 685 location,” said Dr. Stephen Van Roekel, Reginal Medical ...
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... ... 19, 2017 , ... MarkeTouch Media has partnered with fred’s ... a modern design with a more streamlined user experience and is designed to ... app includes hundreds of digital coupons that can be clipped to a customer’s ...
(Date:9/18/2017)... ... , ... TransLuma is a set of dissolving transitions created for use within Final Cut ... luminance of a scene without the use of keyframes. Choose to bleed away ... , TransLuma allows editors to gradually dissolve away the light in a scene to reveal ...
(Date:9/18/2017)... ... , ... A September 7 article on BBC News describes new ... world’s most common and least expensive medications, may be able to stimulate stem cells ... California Dental Group and Calabasas Dental Care says that, while it’s likely to be ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... , Sept. 1, 2017 Michael ... Solutions, Inc , highlights opportunities for growth in his ... report that Marlin Equity is seeking a buyer for ... annual award-winning 22-year-old healthcare solutions Value Added Reseller and ... "As the healthcare market ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices for the ... an Innovative Technology contract from Vizient, Inc., the largest member-driven health ... ... detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based on ...
Breaking Medicine Technology: